Eli Lilly Zepbound Results - Search News

News

Eli Lilly, Zepbound

The Wall Street Journal on MSN · 2d

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Seeking Alpha on MSN · 2d

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial. The detailed results from the 72-week SURMOUNT-5 trial,

Eli Lilly’s Zepbound shows superiority in head-to-head weight loss study

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight reduction targets in a head-to-head study of the two approved weight loss drugs.

Hosted on MSN3d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...

13don MSN

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results